We expect the strong 2020 guidance to support a slight increase to our fair value estimate, but we still don’t expect the stock to look undervalued.
We don't expect a major overhaul of the U.S. healthcare system.
Recent results from some of the most undervalued large drugmakers we cover.
We don't see any major impact to our fair value estimate based on the quarter's outperformance.
We see opportunities in providers, managed care, drugs, and biotech.
The $572 million payment amount for Johnson & Johnson is lower than expected, and the wide-moat firm plans to appeal the case.
The divestment of the generics business should strengthen Pfizer's competitive positioning.
Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.
We're finding some opportunity in a sector that's fairly valued overall.
The first-quarter performance reinforces our wide moat rating.
Even with the recent glyphosate loss, scientific studies still support the product.
Drug manufacturers and healthcare providers offer the most upside.
The continued strong data in multiple cancers reinforces the strength of Keytruda across multiple indications.
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
The wide-moat drugmaker's lower than expected 2019 guidance doesn't dent our view that the firm will be bolstered by an improving pipeline.
We continue to view the stock as undervalued after total sales matched expectations.
The wide-moat firm was leg by its drug unit, but increasing generic pressures weigh on the 2019 outlook.
We don't expect any major changes to our fair value estimate based on the deal, with the expected revenue from acquired cancer drugs offsetting the purchase price and increased R&D expenditures.
We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
While we believe the restructuring makes strategic sense, the related one-time costs are higher than we expected.
The sale of noncore consumer assets should allow the firm to focus on other consumer products while the purchase of Tesaro improves its standing in the PARP oncology setting.
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.
We view the company as slightly overvalued but don't expect any major changes to our fair value estimate.
Cost-saving plans and product launches should offset patent losses and drive growth.
We think that Albert Bourla will continue the wide-moat firm's current strategic focus.
Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.
Thanks to strong rare-disease drug data, we've edged up our fair value estimate on the drugmaker.
The market reaction to glyphosate's legal issues looks overdone.
Litigation concerns about glyphosate weedkillers are weighing on Bayer's shares, but we don't expect to make a significant change to our fair value estimate.
The company's entrenched products and developing pipeline are underappreciated.
We don't expect any major changes to our fair value estimate after results were in line with expectations.
The negative news puts increased pressure on AbbVie's remaining pipeline to offset upcoming biosimilar pressures on its key drug Humira.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the second quarter.
The company's board is considering a sale or merger, which would maximize shareholder value and draw out the firm's full potential.
We expect the wide-moat drugmaker to take more share from Bristol, Roche, and AstraZeneca based on cross-trial comparisons that support Keytruda over competitive drugs.
The pricing power of branded drugs in the U.S. still looks strong.